Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer

Documenti analoghi

• Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer
  di: Babiker, Hani M., et al.
  Pubblicazione: (2020)
• Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies
  di: Savona, Michael R., et al.
  Pubblicazione: (2018)
• Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
  di: Garcia-Manero, G, et al.
  Pubblicazione: (2016)
• Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
  di: Garcia-Manero, Guillermo, et al.
  Pubblicazione: (2021)
• Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia
  di: Cogle, Christopher R., et al.
  Pubblicazione: (2015)